CBOE's Weekly Market Recap: Nov.14-18 – Biogen’s Alzheimer’s Drug Captures Investors’ Attention

Ad blocking detected

Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Ultra Club
$500/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.


The market has experienced some relief from bearish price action in November, continuing October’s push to usher the SPDR S&P 500 ETF (NYSEARCA: SPY) toward $400.

Individual stocks have seen some relief as well, particularly in the oil & gas, biotechnology and financial sectors, which continue to show bullish action compared to the general market. The current rally is likely influenced by the latest Consumer Price Index (CPI) and Producer Price Index (PPI) reports, both of which came in below expectations. This arguably indicates that the Federal Reserve’s monetary tightening policies are starting to work.

Cboe Global Markets Inc. (BATS: CBOE) reports that all the exchange-traded funds (ETFs) and indices recorded in this series experienced a price decrease last week as the general market experienced a pullback in its short-term uptrend. Britain’s iShares Core DAX UCITS ETF (BIT: EXS1) and France’s Lyxor CAC 40 ETF (EPA: CAC) were the two exceptions, both experiencing slight increases in the prior week.

The cryptocurrency market has largely mirrored its traditional counterparts, experiencing decreases in Bitcoin (CRYPTO: BTC), Ethereum (CRYPTO: ETH) and Solana (CRYPTO: SOL) — all of which have dropped in value following FTX’s collapse. With uncertainty brimming, Cboe highlights Biogen Inc. (NASDAQ: BIIB) as a chart that may have piqued investor interest following positive clinical trial results for their new Alzheimer’s drug.

Next week will be huge for the fashion retail sector, with many of Wall Street’s top firms reporting earnings. Cboe has compiled a list of earnings for investors to keep an eye on at the bottom of this report.

Keep scrolling to learn more.

Quick BitesExchange-Traded Funds

  • The SPDR S&P 500 ETF (NYSEARCA: SPY) decreased by 0.62% over the previous week.

  • The Invesco QQQ Trust Series 1 (NASDAQ: QQQ) decreased by 1.09% over the previous week, mirroring the SPY’s movements.

  • The iShares Russell 2000 ETF (NASDAQ: IWM) decreased by 1.70% over the previous week.

  • The Cboe Volatility Index™ (INDEXCBOE: VIX) closed at 23.11 last week, a slight increase over last week.

World Markets

  • The iShares Core MSCI Europe ETF (NYSEARCA: IEUR) decreased by 0.63% week-on-week.

  • The iShares FTSE 100 UCITS ETF (LSE: ISF) increased by 0.95% week-on-week.

  • The Lyxor CAC 40 ETF (EPA: CAC) increased by 0.71% week-on-week.

Chart Of The Week: BIIB

This photo was taken from the TradingView platform

Shares of Biogen skyrocketed on Sept. 22nd after the company announced positive clinical trial results for their Alzheimer’s drug lecanemab. The company said their drug met all key secondary endpoints with highly statistically significant results.

These results have brought Biogen closer to a Federal Drug Agency (FDA) approved Alzheimer’s drug, a feat several biopharmaceutical companies are competing to achieve. Investors responded enthusiastically to this information. Biogen’s trading volume on the 28th of September hit 7.111 million shares, a 1,500% positive deviation off of the 50-day average trading volume of 331,000.

The stock’s price slingshotted 50% overnight – rising to $284 a share – and, since then, has drifted toward $300. According to Grand View Research, the Alzheimer’s therapy market was valued at $4.04 billion in 2021 and is expected to grow at a 16.2% compound annual growth rate from 2022 to 2030.

Major Cryptocurrencies

  • Bitcoin has decreased by 0.33% since the previous week, consolidating after FTX’s collapse.

  • Ethereum has decreased by 6.4% since last week.

  • Solana has decreased by 6.91% since last week.

Upcoming Earnings Releases

A number of companies report earnings next week, including:


Earnings per share (EPS) estimate

Dell Technologies Inc. (NYSE: DELL)



Zoom Video Communications Inc. (NASDAQ: ZM)



Urban Outfitters Inc. (NASDAQ: URBN)



Best Buy Co. (NYSE: BBY)



Helmerich & Payne, Inc. (NASDAQ: HP)



Abercrombie & Fitch (NYSE: ANF)


Dick’s Sporting Goods Inc. (NYSE: DKS)



Nordstrom Inc. (NYSE: JWN)



Click here for more weekly insights by Cboe.

This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice.

Contact Details

Michele Ormont

[email protected]

Company Website


Copyright (c) 2022 TheNewswire - All rights reserved.